Calcineurin inhibitors in heart transplantation

Journal of Heart and Lung Transplantation

Volumn 23, Issue 5 SUPPL., 2004, Pages

  Keogh, Anne ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b Victor Chang Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; GRAFT FAILURE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; MICROEMULSION; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

EID: 1942484480     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2004.03.008     Document Type: Article

References (38)

1. Hertz M.I., Mohacsi P.J., Taylor D.O., et al. The Registry of the International Society for Heart and Lung Transplantation Introduction to the twentieth annual reports - 2003. J Heart Lung Transplant. 22:2003;610-615.
2. ISHLT 2003 quarterly data report. www.ishlt.org/registries. Accessed January 2004.
3. Taylor D.O., Edwards L.B., Mohacsi P.J., et al. The Registry of the International Society for Heart and Lung Transplantation Twentieth official adult heart transplant report - 2003. J Heart Lung Transplant. 22:2003;616-624.
4. Moien-Afshari F., McManus B.M., Laher I. Immunosuppression and transplant vascular disease Benefits and adverse effects. Pharmacol Ther. 100:2003;141-156.
5. Kahan B.D., Welsh M., Schoenberg L., et al. Variable absorption of cyclosporine A biological risk factor for chronic allograft rejection. Transplantation. 62:1996;599-606.
6. Banner N.R., David O.J., Leaver N., et al. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Transplant Int. 15:2002;649-654.
7. Eisen H.J., Hobbs R.E., Davis S.F., et al. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients A randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine - results at six months after transplantation. Transplantation. 68:1999;663-671.
8. Grimm M., Rinaldi M., Yonan N.A., the European Tacrolimus Heart Study Group. Efficacy and safety of tacrolimus (TAC) vs. cyclosporine microemulsion (CME) in de novo cardiac transplant recipients 6 month results. J Heart Lung Transplant. 22:(suppl 1):2003;92.
9. Pham S.M., Kormos R.L., Hattler B.G., et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation Intermediate-term results. J Thorac Cardiovasc Surg. 111:1996;764-772.
10. Meisner B.M., Überfuhr P., Fuchs A., et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant. 17:1998;782-788.
11. Reichart B., Meiser B., Vigano M., et al. European multicenter tacrolimus (FK506) heart pilot study One-year results - european tacrolimus multicenter heart study group. J Heart Lung Transplant. 17:1998;775-781.
12. Taylor D.O., Barr M.L., Radovancevic B. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation Decreased hyperlipidemia and hypertension with tacrolimus. J Thorac Cardiovasc Surg. 18:1999;336-345.
13. Clase C.M., Mahalati K., Kiberd B.A., et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection Patients monitored by absorption profiling. Am J Transplant. 2:2002;789-795.
14. Koglin J., Muscholl M., Petrakopoulou P., et al. Tacrolimus excels cyclosporine in prevention of cardiac allograft vasculopathy A prospective ivus, angiography and doppler study. J Heart Lung Transplant. 21:2002;68.
15. Klauss V., König A., Spes C., et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. Am J Cardiol. 85:2000;266-269.
16. Young J.B. Allograft vasculopathy Diagnosing the nemesis of heart transplantation. Circulation. 100:1999;458-460.
17. Costanzo M.R., Naftel D.C., Pritzker M.R. Heart transplant coronary artery disease detected by coronary angiography A multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant. 17:1998;744-753.
18. Tuzcu E.M., Starling R., Dorent R., et al. Everolimus (Certican, RAD) reduces cardiac allograft vasculopathy. The Heart Intravascular Ultrasound Study. (Abstract) Am J Transplant. 2:(Suppl 3):2002;459.
19. Kobashigawa J.A. First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation. J Heart Lung Transplant. 22:2003;711-714.
20. French C.G., Belitsky P., Lawen J.G. Progress in renal transplantation. Can J Urol. 7:2000;1030-1037.
21. Peraira J.R., Segovia J., Arroyo R., et al. High incidence of severe infections in heart transplant recipients receiving tacrolimus. Transplant Proc. 35:2003;1999-2000.
22. Crespo-Leiro M.G. Tacrolimus in heart transplantation. Transplant Proc. 35:2003;1981-1983.
23. Davidson J., Wilkinson A., Dantal J., et al. New onset diabetes after transplantation 2003 international consensus guidelines. Transplantation. 75:(suppl):2003;SS3-S24.
24. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients Am J Transplant. 3:2001;590-598.
25. Hathout E.H., Chinnock R.E., Johnston J.K., et al. Pediatric post-transplant diabetes Data from a large cohort of pediatric heart-transplant patients. Am J Transplant. 3:2003;994-998.
26. Teebken O.E., Struber M., Harringer W., et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients. Transplant Proc. 34:2002;1265-1268.
27. Rinaldi M., Pellegrini C., Martinelli L., et al. FK506 effectiveness in reducing acute rejection after heart transplantation A prospective randomized study. J Heart Lung Transplant. 16:1997;1001-1010.
28. Czerny M., Sahlin V., Fasching P., et al. The impact of diabetes mellitus at the time of heart transplantation on long-term survival. Diabetologia. 45:2002;1498-1508.
29. Kwok BW-K, Cantin B, Chan MC-Y, et al. Patients with diabetes have poorer survival after heart transplantation - 15 year analysis. Clin Sci 2003;I-395.
30. Valantine H., Rickenbacker P., Kemna M., et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease. Circulation. 103:2001;2144-2152.
31. Lang C.C., Beniaminovitz A., Edwards N., Mancini D.M. Morbidity and mortality in diabetic patients following cardiac transplantation. J Heart Lung Transplant. 22:2003;244-249.
32. Hricik D.E., Mayes J.T., Schulak J.A. Independent effects of cyclosporine and prednisone on posttransplant hyperlipidemia. Am J Kidney Dis. 18:1991;353-358.
33. Keogh A., Macdonald P., Harvison A., et al. Initial steroid-free versus steroid-based maintenance therapy and steroid withdrawal after heart transplantation Two views of the steroid question. J Heart Lung Transplant. 11:1992;421-427.
34. Locsey L., Asztalos L., Kincses Z., et al. The importance of obesity and hyperlipidaemia in patients with renal transplants. Int Urol Nephrol. 30:1998;767-775.
35. Kobashigawa J., Miller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation. 66:1998;507-515.
36. Keogh A., Bourge B., Costanzo M., et al. Three year results of the mycophenolate mofetil randomized trial in heart transplant recipients. J Heart Lung Transplant. 18:1999;53.
37. Hosenpud J.D., Bennett L.E. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization An analysis of the joint unos/ishlt thoracic registry. Transplantation. 72:2001;1662-1665.
38. Taylor D.O., Sharma R.C., Kfoury A.G., Renlund D.G. Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine. Clin Transplant. 13:1999;296-299.